BidaskClub upgraded shares of NewLink Genetics (NASDAQ:NLNK) from a sell rating to a hold rating in a report published on Friday, January 5th.
Other equities analysts have also issued research reports about the company. ValuEngine lowered NewLink Genetics from a sell rating to a strong sell rating in a research note on Tuesday, September 26th. Zacks Investment Research raised NewLink Genetics from a hold rating to a buy rating and set a $10.00 price target on the stock in a research note on Tuesday, November 7th. Jefferies Group upgraded NewLink Genetics from a hold rating to a buy rating and boosted their price objective for the company from $7.00 to $26.00 in a report on Friday, September 8th. Cantor Fitzgerald reiterated a buy rating and issued a $26.00 price objective on shares of NewLink Genetics in a report on Monday, September 25th. Finally, Stifel Nicolaus boosted their price objective on NewLink Genetics from $25.00 to $29.00 and gave the company a buy rating in a report on Friday, November 3rd. One analyst has rated the stock with a sell rating, two have given a hold rating and six have given a buy rating to the stock. The company has an average rating of Buy and a consensus target price of $23.29.
Shares of NewLink Genetics (NASDAQ NLNK) traded down $0.16 during trading hours on Friday, hitting $8.25. The stock had a trading volume of 553,572 shares, compared to its average volume of 777,704. The firm has a market capitalization of $298.83, a price-to-earnings ratio of -3.38 and a beta of 1.10. NewLink Genetics has a 12-month low of $5.90 and a 12-month high of $25.17.
Hedge funds and other institutional investors have recently modified their holdings of the business. Zurcher Kantonalbank Zurich Cantonalbank increased its holdings in NewLink Genetics by 1,823.0% during the 3rd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 10,269 shares of the biotechnology company’s stock worth $105,000 after purchasing an additional 9,735 shares during the period. Oppenheimer & Co. Inc. purchased a new stake in NewLink Genetics during the 3rd quarter worth about $114,000. State of Wisconsin Investment Board purchased a new stake in NewLink Genetics during the 2nd quarter worth about $125,000. Advisor Group Inc. increased its holdings in NewLink Genetics by 3.4% during the 2nd quarter. Advisor Group Inc. now owns 18,082 shares of the biotechnology company’s stock worth $133,000 after purchasing an additional 600 shares during the period. Finally, Creative Planning acquired a new position in shares of NewLink Genetics during the 4th quarter worth about $152,000. Institutional investors own 52.68% of the company’s stock.
About NewLink Genetics
NewLink Genetics Corporation is a clinical-stage immuno-oncology company focused on discovering, developing and commercializing immunotherapeutic products for the treatment of cancer. The Company’s portfolio includes biologic and small-molecule immunotherapy product candidates for a range of oncology indications.
Receive News & Ratings for NewLink Genetics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NewLink Genetics and related companies with MarketBeat.com's FREE daily email newsletter.